{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:49:05Z","timestamp":1782031745268,"version":"3.54.5"},"reference-count":150,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bbcan.2026.189564","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:16:18Z","timestamp":1771546578000},"page":"189564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies"],"prefix":"10.1016","volume":"1881","author":[{"given":"Xiaoxuan","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luqi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshuo","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengjuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0010","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41392-024-02097-4","article-title":"Digestive cancers: mechanisms, therapeutics and management","volume":"10","author":"Zhan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0015","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0020","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12964-022-00854-y","article-title":"Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons","volume":"20","author":"Naimi","year":"2022","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189564_bb0035","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/s41416-023-02437-1","article-title":"Checkpoint inhibitors and anti-angiogenic agents: a winning combination","volume":"129","author":"Brest","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189564_bb0040","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1111\/bph.16232","article-title":"Natural products targeting tumour angiogenesis","volume":"182","author":"Lu","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0045","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/med.21876","article-title":"Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: helping to fight against cancer via multiple targets","volume":"42","author":"Zhong","year":"2022","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10456-017-9541-1","article-title":"The role of vasculature in bone development, regeneration and proper systemic functioning","volume":"20","author":"Filipowska","year":"2017","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbcan.2026.189564_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.addr.2018.09.010","article-title":"Therapeutic strategies for enhancing angiogenesis in wound healing","volume":"146","author":"Veith","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.bbcan.2026.189564_bb0060","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12964-022-00838-y","article-title":"Cancer combination therapies by angiogenesis inhibitors; a comprehensive review","volume":"20","author":"Ansari","year":"2022","journal-title":"Cell Commun. Signal"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189564_bb0070","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.bbcan.2026.189564_bb0075","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.3390\/cancers13143433","article-title":"The anti-VEGF(R) drug discovery legacy: improving attrition rates by breaking the vicious cycle of angiogenesis in cancer","volume":"13","author":"Ribatti","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0080","first-page":"71","article-title":"Ramucirumab: a new therapy for advanced gastric cancer","volume":"6","author":"Oholendt","year":"2015","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.bbcan.2026.189564_bb0085","doi-asserted-by":"crossref","unstructured":"A.X. Zhu, Y.K. Kang, C.J. Yen, R.S. Finn, P.R. Galle, J.M. Llovet, E. Assenat, G. Brandi, M. Pracht, H.Y. Lim, K.M. Rau, K. Motomura, I. Ohno, P. Merle, B. Daniele, D.B. Shin, G. Gerken, C. Borg, J.B. Hiriart, T. Okusaka, M. Morimoto, Y. Hsu, P.B. Abada, M. Kudo, R.-s. investigators, Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol. 20(2) (2019) 282\u2013296.","DOI":"10.1016\/S1470-2045(18)30937-9"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189564_bb0090","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor a","volume":"24","author":"Perez-Gutierrez","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189564_bb0095","doi-asserted-by":"crossref","first-page":"15585","DOI":"10.3390\/ijms232415585","article-title":"The VEGF\/VEGFR axis revisited: implications for cancer therapy","volume":"23","author":"Mabeta","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189564_bb0100","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.3390\/ijms23073645","article-title":"Vascular permeability in diseases","volume":"23","author":"Wautier","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.bbcan.2026.189564_bb0105","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.3390\/molecules27175537","article-title":"Small molecule inhibitors for hepatocellular carcinoma: advances and challenges","volume":"27","author":"Kamal","year":"2022","journal-title":"Molecules"},{"issue":"13","key":"10.1016\/j.bbcan.2026.189564_bb0110","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of Apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189564_bb0115","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S2468-1253(21)00109-6","article-title":"Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"6","author":"Qin","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9863","key":"10.1016\/j.bbcan.2026.189564_bb0120","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189564_bb0125","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1093\/oncolo\/oyac271","article-title":"Activity of anlotinib in the second-line therapy of metastatic gastrointestinal stromal tumors: a prospective, multicenter, in vitro study","volume":"28","author":"Zhou","year":"2023","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0130","doi-asserted-by":"crossref","first-page":"e484","DOI":"10.1002\/onco.13566","article-title":"FDA supplemental approval summary: lenvatinib for the treatment of unresectable hepatocellular carcinoma","volume":"26","author":"Nair","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41392-024-02085-8","article-title":"Efficacy and safety of lenvatinib plus gefitinib in lenvatinib-resistant hepatocellular carcinomas: a prospective, single-arm exploratory trial","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189564_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153455","article-title":"Quercetin inhibits invasion and angiogenesis of esophageal cancer cells","volume":"222","author":"Liu","year":"2021","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbcan.2026.189564_bb0145","doi-asserted-by":"crossref","first-page":"7447","DOI":"10.2147\/OTT.S256291","article-title":"Parthenolide inhibits angiogenesis in Esophageal squamous cell carcinoma through suppression of VEGF","volume":"13","author":"Tian","year":"2020","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bbcan.2026.189564_bb0150","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.2147\/DDDT.S269915","article-title":"Pseudolaric acid B inhibits proliferation, invasion, and angiogenesis in Esophageal squamous cell carcinoma through regulating CD147","volume":"14","author":"Yin","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"issue":"43","key":"10.1016\/j.bbcan.2026.189564_bb0155","doi-asserted-by":"crossref","first-page":"74673","DOI":"10.18632\/oncotarget.20341","article-title":"Metformin inhibits esophageal squamous cell carcinoma-induced angiogenesis by suppressing JAK\/STAT3 signaling pathway","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0160","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.bbrc.2017.06.140","article-title":"Luteolin suppresses angiogenesis and vasculogenic mimicry formation through inhibiting Notch1-VEGF signaling in gastric cancer","volume":"490","author":"Zang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189564_bb0165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bbrc.2021.08.092","article-title":"Crocetin suppresses angiogenesis and metastasis through inhibiting sonic hedgehog signaling pathway in gastric cancer","volume":"576","author":"Zang","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189564_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112086","article-title":"Ginsenoside Rg3 inhibits angiogenesis in gastric precancerous lesions through downregulation of Glut1 and Glut4","volume":"145","author":"Zeng","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189564_bb0175","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3389\/fphar.2017.00783","article-title":"Ginsenoside-Rb1-mediated anti-angiogenesis via regulating PEDF and miR-33a through the activation of PPAR-\u03b3 pathway","volume":"8","author":"Lu","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189564_bb0180","first-page":"1159","article-title":"Tanshinone IIA reduces secretion of pro-angiogenic factors and inhibits angiogenesis in human colorectal cancer","volume":"43","author":"Zhou","year":"2020","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189564_bb0185","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2017.05.013","article-title":"Tanshinone IIA inhibits beta-catenin\/VEGF-mediated angiogenesis by targeting TGF-beta1 in normoxic and HIF-1alpha in hypoxic microenvironments in human colorectal cancer","volume":"403","author":"Sui","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189564_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116299","article-title":"The extract of Curcumae longae Rhizoma suppresses angiogenesis via VEGF-induced PI3K\/Akt-eNOS-NO pathway","volume":"308","author":"Guo","year":"2023","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bbcan.2026.189564_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109491","article-title":"Epigallocatechin-3-gallate inhibits tumor angiogenesis: involvement of endoglin\/Smad1 signaling in human umbilical vein endothelium cells","volume":"120","author":"Chen","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189564_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216596","article-title":"Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3beta\/TCF7\/MMP9 pathway and synergies with capecitabine","volume":"582","author":"Dai","year":"2024","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.bbcan.2026.189564_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.84","article-title":"Combination curcumin and (\u2212)-epigallocatechin-3-gallate inhibits colorectal carcinoma microenvironment-induced angiogenesis by JAK\/STAT3\/IL-8 pathway","volume":"6","author":"Jin","year":"2017","journal-title":"Oncogenesis"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189564_bb0210","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cells11091502","article-title":"Crocin inhibits angiogenesis and metastasis in colon cancer via TNF-alpha\/NF-kB\/VEGF pathways","volume":"11","author":"Bakshi","year":"2022","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0215","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/biomedicines11010188","article-title":"Sesamin attenuates VEGFA-induced angiogenesis via inhibition of Src and FAK signaling in chick chorioallantoic membrane model and human endothelial EA.hy926 cells","volume":"11","author":"Keratibumrungpong","year":"2023","journal-title":"Biomedicines"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189564_bb0220","doi-asserted-by":"crossref","first-page":"8989","DOI":"10.1039\/D2FO00345G","article-title":"Sesamin inhibits hypoxia-stimulated angiogenesis via the NF-kappaB p65\/HIF-1alpha\/VEGFA signaling pathway in human colorectal cancer","volume":"13","author":"Huang","year":"2022","journal-title":"Food Funct."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189564_bb0225","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.3892\/ijmm.2014.1669","article-title":"Parthenolide exerts inhibitory effects on angiogenesis through the downregulation of VEGF\/VEGFRs in colorectal cancer","volume":"33","author":"Kim","year":"2014","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0230","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s10020-024-01032-1","article-title":"Natural flavonoid orientin restricts 5-fluorouracil induced cancer stem cells mediated angiogenesis by regulating HIF1alpha and VEGFA in colorectal cancer","volume":"31","author":"Ghosh","year":"2025","journal-title":"Mol. Med."},{"key":"10.1016\/j.bbcan.2026.189564_bb0235","first-page":"3815786","article-title":"Ginsenoside Rg3 prolongs survival of the orthotopic hepatocellular carcinoma model by inducing apoptosis and inhibiting angiogenesis","volume":"2019","author":"Hu","year":"2019","journal-title":"Anal. Cell. Pathol. (Amst.)"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189564_bb0240","doi-asserted-by":"crossref","first-page":"9289","DOI":"10.3390\/ijms22179289","article-title":"(20S) ginsenoside Rh2 inhibits STAT3\/VEGF signaling by targeting annexin A2","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189564_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.112852","article-title":"The epigallocatechin gallate derivative Y(6) inhibits human hepatocellular carcinoma by inhibiting angiogenesis in MAPK\/ERK1\/2 and PI3K\/AKT\/ HIF-1alpha\/VEGF dependent pathways","volume":"259","author":"Liao","year":"2020","journal-title":"J. Ethnopharmacol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189564_bb0250","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/ptr.7427","article-title":"Myricetin reverses epithelial-endothelial transition and inhibits vasculogenic mimicry and angiogenesis of hepatocellular carcinoma by directly targeting PAR1","volume":"36","author":"Wang","year":"2022","journal-title":"Phytother. Res."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189564_bb0255","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.7150\/jca.33704","article-title":"Dihydroartemisinin induces endothelial cell autophagy through suppression of the Akt\/mTOR pathway","volume":"10","author":"Liu","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189564_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175158","article-title":"Novel artemisinin derivative FO8643 with anti-angiogenic activity inhibits growth and migration of cancer cells via VEGFR2 signaling","volume":"930","author":"Lu","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189564_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110062","article-title":"Artemisinin derivative FO-ARS-123 as a novel VEGFR2 inhibitor suppresses angiogenesis, cell migration, and invasion","volume":"365","author":"Lu","year":"2022","journal-title":"Chem. Biol. Interact."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189564_bb0270","doi-asserted-by":"crossref","first-page":"15904","DOI":"10.3390\/ijms232415904","article-title":"Thymoquinone suppresses angiogenesis in DEN-induced hepatocellular carcinoma by targeting miR-1-3p","volume":"23","author":"Tadros","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189564_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2024.119180","article-title":"Angiogenic protein profiling, phytochemical screening and in silico anti-cancer targets validation of stem, leaves, fruit, and seeds of Calotropis procera in human liver and breast cancer cell lines","volume":"256","author":"Khan","year":"2024","journal-title":"Environ. Res."},{"key":"10.1016\/j.bbcan.2026.189564_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114219","article-title":"Antiangiogenic potential of Lepista nuda extract suppressing MAPK\/p38 signaling-mediated developmental angiogenesis in zebrafish and HUVECs","volume":"159","author":"Deshmukh","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189564_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155402","article-title":"Ginsenoside Rg3 suppresses vasculogenic mimicry by impairing DVL3-maintained stemness via PAAD cell-derived exosomal miR-204 in pancreatic adenocarcinoma","volume":"126","author":"Cai","year":"2024","journal-title":"Phytomedicine"},{"issue":"19","key":"10.1016\/j.bbcan.2026.189564_bb0290","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.3390\/molecules26196033","article-title":"Anticancer effects of the Corchorus olitorius aqueous extract and its bioactive compounds on human cancer cell lines","volume":"26","author":"Tosoc","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bbcan.2026.189564_bb0295","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.actbio.2022.12.022","article-title":"Bioactive lipid-nanoparticles with inherent self-therapeutic and anti-angiogenic properties for cancer therapy","volume":"157","author":"Cao","year":"2023","journal-title":"Acta Biomater."},{"key":"10.1016\/j.bbcan.2026.189564_bb0300","doi-asserted-by":"crossref","first-page":"14057","DOI":"10.2147\/IJN.S544668","article-title":"Co-delivery of chemotherapy and anti-angiogenic lipid via DPPA-LNPs potentiates anti-PD-1 immunotherapy","volume":"20","author":"Tan","year":"2025","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.bbcan.2026.189564_bb0305","doi-asserted-by":"crossref","DOI":"10.1093\/rb\/rbae036","article-title":"A lipid\/PLGA nanocomplex to reshape tumor immune microenvironment for colon cancer therapy","volume":"11","author":"Zhang","year":"2024","journal-title":"Regener. Biomater."},{"issue":"26","key":"10.1016\/j.bbcan.2026.189564_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202401436","article-title":"Bioactive nanotherapeutic ultrasound contrast agent for concurrent breast cancer ultrasound imaging and treatment","volume":"13","author":"Fang","year":"2024","journal-title":"Adv. Healthc. Mater."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0315","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12951-025-03577-7","article-title":"Delivery of an ERK inhibitor using bioactive lipid nanoparticles reduces angiogenesis and prevents oral squamous cell carcinoma development","volume":"23","author":"Huang","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0320","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0325","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189564_bb0330","article-title":"Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0335","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13129","article-title":"Targeting regulatory T cells in anti-PD-1\/PD-L1 cancer immunotherapy","volume":"95","author":"Zhulai","year":"2022","journal-title":"Scand. J. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0340","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.immuni.2018.06.012","article-title":"PD-1 controls follicular T helper cell positioning and function","volume":"49","author":"Shi","year":"2018","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189564_bb0345","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","article-title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Kato","year":"2019","journal-title":"Lancet Oncol."},{"issue":"10294","key":"10.1016\/j.bbcan.2026.189564_bb0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"16_Supplement","key":"10.1016\/j.bbcan.2026.189564_bb0355","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1158\/1538-7445.AM2020-3260","article-title":"Abstract 3260: the preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation","volume":"80","author":"Zhang","year":"2020","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189564_bb0360","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/jama.2024.28463","article-title":"First-line sugemalimab plus chemotherapy for advanced gastric cancer: the GEMSTONE-303 randomized clinical trial","author":"Zhang","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0365","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000515553","article-title":"Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: a subgroup analysis of Asian patients in the phase 3 KEYNOTE-240 trial","volume":"10","author":"Kudo","year":"2021","journal-title":"Liver Cancer"},{"issue":"23","key":"10.1016\/j.bbcan.2026.189564_bb0370","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189564_bb0375","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang","year":"2020","journal-title":"Lancet Oncol."},{"issue":"27","key":"10.1016\/j.bbcan.2026.189564_bb0380","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of Tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0385","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0390","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0395","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J. Hepatol."},{"issue":"15","key":"10.1016\/j.bbcan.2026.189564_bb0400","doi-asserted-by":"crossref","first-page":"16066","DOI":"10.1002\/cam4.6260","article-title":"Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma","volume":"12","author":"Lee","year":"2023","journal-title":"Cancer Med."},{"issue":"10088","key":"10.1016\/j.bbcan.2026.189564_bb0405","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.bbcan.2026.189564_bb0410","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0415","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.annonc.2024.10.829","volume":"36","author":"Lordick","year":"2025","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0420","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.bbcan.2026.189564_bb0425","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41590-023-01569-z","article-title":"LAG-3 as the third checkpoint inhibitor","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189564_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100639","article-title":"A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer","volume":"7","author":"Garralda","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189564_bb0435","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2026.189564_bb0440","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","article-title":"Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial","volume":"30","author":"de Gooyer","year":"2024","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189564_bb0445","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008689","article-title":"Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study","volume":"12","author":"Overman","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"17","key":"10.1016\/j.bbcan.2026.189564_bb0450","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid Tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189564_bb0455","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","article-title":"T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028","volume":"37","author":"Ott","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189564_bb0460","doi-asserted-by":"crossref","first-page":"H751","DOI":"10.1152\/ajpheart.00378.2023","article-title":"Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications","volume":"325","author":"Banerjee","year":"2023","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0465","first-page":"82","article-title":"Role of PD-1\/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy","volume":"11","author":"Godiyal","year":"2024","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.bbcan.2026.189564_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154672","article-title":"Liujunzi decoction exerts potent antitumor activity in oesophageal squamous cell carcinoma by inhibiting miR-34a\/STAT3\/IL-6R feedback loop, and modifies antitumor immunity","volume":"111","author":"Han","year":"2023","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0475","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3892\/ijmm.2021.4998","article-title":"Banxia xiexin decoction affects drug sensitivity in gastric cancer cells by regulating MGMT expression via IL-6\/JAK\/STAT3-mediated PD-L1 activity","volume":"48","author":"Feng","year":"2021","journal-title":"Int. J. Mol. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0480","doi-asserted-by":"crossref","first-page":"11560","DOI":"10.1038\/s41598-019-47903-0","article-title":"Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico","volume":"9","author":"Mazewski","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189564_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104727","article-title":"Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1alpha and STAT3 in human colon cancer cells","volume":"155","author":"Wang","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0490","article-title":"Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189564_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155370","article-title":"Uncovering the colorectal cancer immunotherapeutic potential: evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1\/PD-L1 blockade","volume":"125","author":"Lee","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bbcan.2026.189564_bb0500","doi-asserted-by":"crossref","first-page":"10917","DOI":"10.2147\/OTT.S212666","article-title":"Triterpenoid saponins from Anemone flaccida suppress tumor cell proliferation by regulating MAPK, PD1\/PDL1, and STAT3 Signaling pathways and altering cancer metabolism","volume":"12","author":"Han","year":"2019","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.bbcan.2026.189564_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105824","article-title":"Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells","volume":"75","author":"Ke","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2026.189564_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2024.118278","article-title":"The mechanism of Xihuang pills' intervention in the tumour immune microenvironment for the treatment of liver cancer based on the STAT3-PDL1 pathway","volume":"331","author":"Wang","year":"2024","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0515","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/01635581.2023.2276525","article-title":"Radix Bupleuri-Radix Paeoniae Alba inhibits the development of hepatocellular carcinoma through activation of the PTEN\/PD-L1 Axis within the immune microenvironment","volume":"76","author":"Zhang","year":"2024","journal-title":"Nutr. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189564_bb0520","doi-asserted-by":"crossref","first-page":"868","DOI":"10.2174\/1568009620999200730184514","article-title":"Pentamethylquercetin inhibits hepatocellular carcinoma progression and adipocytes-induced PD-L1 expression via IFN-gamma signaling","volume":"20","author":"Li","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0525","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3639","article-title":"Akkermansia muciniphila might improve anti-PD-1 therapy against HCC by changing host bile acid metabolism","volume":"26","author":"Lan","year":"2024","journal-title":"J. Gene Med."},{"issue":"23","key":"10.1016\/j.bbcan.2026.189564_bb0530","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202207201","article-title":"Nano-econazole enhanced PD-L1 checkpoint blockade for synergistic antitumor immunotherapy against pancreatic ductal adenocarcinoma","volume":"19","author":"Li","year":"2023","journal-title":"Small"},{"issue":"11","key":"10.1016\/j.bbcan.2026.189564_bb0535","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0540","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbcan.2026.189564_bb0545","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1038\/ncomms7340","article-title":"The HIF-1\/glial TIM-3 axis controls inflammation-associated brain damage under hypoxia","volume":"6","author":"Koh","year":"2015","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0550","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ijc.30077","article-title":"PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma","volume":"139","author":"Ruf","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189564_bb0555","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/hep.30889","article-title":"Dual programmed death Receptor-1 and vascular endothelial growth factor Receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma","volume":"71","author":"Shigeta","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0560","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS ONE"},{"issue":"385","key":"10.1016\/j.bbcan.2026.189564_bb0570","doi-asserted-by":"crossref","first-page":"eaak9670","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189564_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107929","article-title":"PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer","volume":"99","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189564_bb0580","doi-asserted-by":"crossref","first-page":"eaay7785","DOI":"10.1126\/sciadv.aay7785","article-title":"Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-\u03baB inhibitor for antitumor immunotherapy","volume":"6","author":"Xiao","year":"2020","journal-title":"Sci. Adv."},{"issue":"Pt 3","key":"10.1016\/j.bbcan.2026.189564_bb0585","article-title":"Preparation and anti-tumor ability evaluation of anti-PD-L1 conjugated curcumin in colon cancer","volume":"306","author":"Ding","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"24","key":"10.1016\/j.bbcan.2026.189564_bb0590","doi-asserted-by":"crossref","first-page":"15125","DOI":"10.1021\/acs.jafc.5c01821","article-title":"Combination of ginsenoside compound K and anti-PD1 inhibits pancreatic cancer by activating CXCL13-CXCR5 Signaling Axis","volume":"73","author":"Shang","year":"2025","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bbcan.2026.189564_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106988","article-title":"Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8(+) T cells via increasing intratumoral CXCL10","volume":"198","author":"Huang","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0600","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41467-019-09221-x","article-title":"Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors","volume":"10","author":"Duan","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189564_bb0605","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/ptr.7695","article-title":"Dihydroartemisinin broke the tumor immunosuppressive microenvironment by inhibiting YAP1 expression to enhance anti-PD-1 efficacy","volume":"37","author":"Peng","year":"2023","journal-title":"Phytother. Res."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0610","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2174\/1570161116666180209113014","article-title":"Anti-angiogenic activity of curcumin in cancer therapy: a narrative review","volume":"17","author":"Shakeri","year":"2019","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189564_bb0615","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.3390\/ijms25073735","article-title":"The tumor microenvironment mediates the HIF-1\u03b1\/PD-L1 pathway to promote immune escape in colorectal cancer","volume":"25","author":"Sun","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189564_bb0620","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2025.120511","article-title":"Effectiveness and mechanisms of curcumin for colorectal cancer in preclinical models: a systematic review andmeta-analysis","volume":"354","author":"Jia","year":"2026","journal-title":"J. Ethnopharmacol."},{"issue":"6","key":"10.1016\/j.bbcan.2026.189564_bb0625","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.3390\/ijms26062593","article-title":"Anti-colorectal cancer activity of Panax and its active components, ginsenosides: a review","volume":"26","author":"Kang","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189564_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112069","article-title":"EGCG suppresses PD-1 expression of T cells via inhibiting NF-\u03baB phosphorylation and nuclear translocation","volume":"133","author":"Li","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"20","key":"10.1016\/j.bbcan.2026.189564_bb0635","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10415","key":"10.1016\/j.bbcan.2026.189564_bb0640","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0645","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1470-2045(24)00679-X","article-title":"Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-liver): a randomised, open-label, phase 1b-2, study","volume":"26","author":"Finn","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189564_bb0650","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2022.03.026","article-title":"A phase I\/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer","volume":"169","author":"Kim","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"18","key":"10.1016\/j.bbcan.2026.189564_bb0655","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1200\/JCO.19.03296","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603)","volume":"38","author":"Fukuoka","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0660","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41591-024-02824-y","article-title":"Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial","volume":"30","author":"Kim","year":"2024","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2026.189564_bb0665","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004656","article-title":"Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial","volume":"10","author":"Xia","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2026.189564_bb0670","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(21)00378-2","article-title":"Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial","volume":"7","author":"Meng","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0675","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.bbcan.2026.189564_bb0680","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S1470-2045(20)30271-0","article-title":"Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial","volume":"21","author":"Kawazoe","year":"2020","journal-title":"Lancet Oncol."},{"issue":"26","key":"10.1016\/j.bbcan.2026.189564_bb0685","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of Lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"10474","key":"10.1016\/j.bbcan.2026.189564_bb0690","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","article-title":"Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study","volume":"405","author":"Kudo","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189564_bb0695","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(25)00190-1","article-title":"Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial","volume":"26","author":"Zhou","year":"2025","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0700","doi-asserted-by":"crossref","first-page":"2582294","DOI":"10.1080\/21645515.2025.2582294","article-title":"Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma","volume":"21","author":"Luo","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.bbcan.2026.189564_bb0705","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41392-024-01857-6","article-title":"First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel\/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial","volume":"9","author":"Sha","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.bbcan.2026.189564_bb0710","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41568-024-00705-7","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2026.189564_bb0715","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2026.189564_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189079","article-title":"VEGF signaling: role in angiogenesis and beyond","volume":"1879","author":"Shaw","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2026.189564_bb0725","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/diagnostics11040640","article-title":"Nephrotoxicity of anti-angiogenic therapies","volume":"11","author":"Van Wynsberghe","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"10.1016\/j.bbcan.2026.189564_bb0730","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/his.13716","article-title":"Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy","volume":"73","author":"Pfister","year":"2018","journal-title":"Histopathology"},{"key":"10.1016\/j.bbcan.2026.189564_bb0735","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2020.12.031","article-title":"Angiotensin-converting enzyme inhibitors have adverse effects in anti-angiogenesis therapy for hepatocellular carcinoma","volume":"501","author":"Zhang","year":"2021","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189564_bb0740","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","article-title":"Immune-related serious adverse events with immune checkpoint inhibitors: systematic review and network meta-analysis","volume":"80","author":"Oliveira","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbcan.2026.189564_bb0745","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/bioengineering9050197","article-title":"Flavonoids-based delivery systems towards cancer therapies","volume":"9","author":"Ferreira","year":"2022","journal-title":"Bioengineering (Basel)"},{"key":"10.1016\/j.bbcan.2026.189564_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113384","article-title":"Plant-derived bioactive compounds in colon cancer treatment: an updated review","volume":"153","author":"Esmeeta","year":"2022","journal-title":"Biomed. Pharmacother."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:39:40Z","timestamp":1782031180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":150,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0304419X26000363"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189564","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189564"}}